Artículos por temáticas

Chromatin accessibility and transcription dynamics during in vitro astrocyte differentiation of Huntington's Disease Monkey pluripotent stem cells.

Goodnight AV, Kremsky I, Khampang S, Jung YH, Billingsley JM, Bosinger SE, Corces VG, Chan AWS.

Epigenetics Chromatin. 2019 Nov 13;12(1):67. doi: 10.1186/s13072-019-0313-6.

Exploration of a Co-Production Approach to Developing a Walking Group with People with Huntington's Disease.

Jones U, Hamana K, Vougioukalou S, Jones M, Busse M.

Med One. 2019;4(5):e190022. doi: 10.20900/mo.20190022. Epub 2019 Oct 31.

Deterioration of neuroregenerative plasticity in association with testicular atrophy and dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis in Huntington's disease: A putative role of the huntingtin gene in steroidogenesis

Selvaraj K, Manickam N, Kumaran E, Thangadurai K, Elumalai G, Sekar A, Radhakrishnan RK, Kandasamy M.

J Steroid Biochem Mol Biol. 2020 Mar;197:105526. doi: 10.1016/j.jsbmb.2019.105526. Epub 2019 Nov 9.

Awareness of Chorea in Huntington's Disease

Hergert DC, Sanchez-Ramos J, Cimino CR.

J Huntingtons Dis. 2020;9(1):99-103. doi: 10.3233/JHD-190381.

Longitudinal atrophy characterization of cortical and subcortical gray matter in Huntington's disease patients.

Ramirez-Garcia G, Galvez V, Diaz R, Bayliss L, Fernandez-Ruiz J, Campos-Romo A.

Eur J Neurosci. 2019 Nov 9. doi: 10.1111/ejn.14617. [Epub ahead of print]

Longitudinal study revealing motor, cognitive and behavioral decline in a transgenic minipig model of Huntington's disease.

Baxa M, Levinska B, Skrivankova M, Pokorny M, Juhasova J, Klima J, Klempir J, Motlı K J, Juhas S, Ellederova Z.

Dis Model Mech. 2019 Dec 12;13(2). pii: dmm041293. doi: 10.1242/dmm.041293.

The effect of impulsivity and inhibitory control deficits in the saccadic behavior of premanifest Huntington's disease individuals.

Júlio F, Caetano G, Januário C, Castelo-Branco M.

Orphanet J Rare Dis. 2019 Nov 8;14(1):246. doi: 10.1186/s13023-019-1218-y.

Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.

Kedaigle AJ, Reidling JC, Lim RG, Adam M, Wu J, Wassie B, Stocksdale JT, Casale MS, Fraenkel E, Thompson LM.

Hum Mol Genet. 2019 Nov 7. pii: ddz264. doi: 10.1093/hmg/ddz264. [Epub ahead of print]

Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington's disease.

Irvine EE, Katsouri L, Plattner F, Al-Qassab H, Al-Nackkash R, Bates GP, Withers DJ.

Sci Rep. 2019 Nov 6;9(1):16133. doi: 10.1038/s41598-019-52391-3.

Lack of mutant huntingtin in cortical efferents improves behavioral inflexibility and corticostriatal dynamics in Huntington's disease mice.

Estrada-Sánchez AM, Blake CL, Barton SJ, Howe AG, Rebec GV.

J Neurophysiol. 2019 Dec 1;122(6):2621-2629. doi: 10.1152/jn.00777.2018. Epub 2019 Nov 6.

Chorea-like symptoms and high blood concentration of ceftriaxone in a patient undergoing hemodialysis: A case report.

Yokoyama Y, Hosokawa N, Kudo T, Goda H, Ito K, Suzuki M, Funakoshi R.

J Infect Chemother. 2019 Oct 31. pii: S1341-321X(19)30305-8. doi: 10.1016/j.jiac.2019.10.005. [Epub ahead of print]

Implicit learning impairment identified via predictive saccades in Huntington's disease correlates with extended cortico-striatal atrophy.

Vaca-Palomares I, Brien DC, Coe BC, Ochoa-Morales A, Martínez-Ruano L, Munoz DP, Fernandez-Ruiz J.

Cortex. 2019 Dec;121:89-103. doi: 10.1016/j.cortex.2019.06.013. Epub 2019 Jul 12.

Huntington's disease associated resistance to Mn neurotoxicity is neurodevelopmental stage and neuronal lineage dependent.

Joshi P, Bodnya C, Ilieva I, Neely MD, Aschner M, Bowman AB.

Neurotoxicology. 2019 Dec;75:148-157. doi: 10.1016/j.neuro.2019.09.007. Epub 2019 Sep 20.

Multimodal characterization of the visual network in Huntington's disease gene carriers.

Gregory S, Odish OFF, Mayer I, Mills J, Johnson EB, Scahill RI, Rothwell J, Rees G, Long JD, Tabrizi SJ, Roos RAC, Orth M.

Clin Neurophysiol. 2019 Nov;130(11):2053-2059. doi: 10.1016/j.clinph.2019.08.018. Epub 2019 Aug 28.

Lercanidipine boosts the efficacy of mesenchymal stem cell therapy in 3-NP-induced Huntington's disease model rats via modulation of the calcium/calcineurin/NFATc4 and Wnt/β-catenin signalling pathways.

Elbaz EM, Helmy HS, El-Sahar AE, Saad MA, Sayed RH.

Neurochem Int. 2019 Dec;131:104548. doi: 10.1016/j.neuint.2019.104548. Epub 2019 Sep 17.